@article{article_643094, title={THROMBOTIC THROMBOCYTOPENIC PURPURA: A REPORT OF TWO RESISTANCE CASES AND REVIEW OF THE LITERATURE}, journal={İzmir Eğitim ve Araştırma Hastanesi Tıp Dergisi}, volume={19}, pages={56–59}, year={2015}, DOI={10.1002/jca.21325.}, author={Calan, Mehmet and Bilgir, Ferda and Cagliyan, Gulsum and Ozlu, Can and Yüksel, Arif and Bilgir, Oktay}, keywords={Trombotik trombositopenik purpura,rituksimab,tedavi}, abstract={Thrombotic thrombocytopenic purpura TTP is a rare hematological disease, but it is a hematological emergency with fatal consequences if not promptly diagnosed and appropriately treated. Plasmapheresis is the most effective therapy of TTP through which more than 80% of patients have been cured. Immunosuppressive therapy is used for patients who have resistance TTP. Rituximab is an important immune modulator therapy in certain autoimmune and malignant disorders. Herein, we report two patients with resistance TTP to conventional therapy who were successfully treated by rituximab. Using rituximab as part of the standard therapy may be more effective to prevent potential mortality and morbidity of TTP than standard approach}, number={1}, publisher={İzmir Bozyaka Eğitim ve Araştırma Hastanesi}